171 related articles for article (PubMed ID: 30047807)
1. New strategies for patenting biological medicines used in rheumatoid arthritis treatment.
Oliveira RA; Fierro IM
Expert Opin Ther Pat; 2018 Aug; 28(8):635-646. PubMed ID: 30047807
[TBL] [Abstract][Full Text] [Related]
2. Analysis of patents on anti-rheumatoid arthritis therapies issued in China.
Yuan HY; Zhang XL; Zhang XH; Meng L; Wei JF
Expert Opin Ther Pat; 2015; 25(8):909-30. PubMed ID: 26066366
[TBL] [Abstract][Full Text] [Related]
3. [Targeting CD20 in rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
[TBL] [Abstract][Full Text] [Related]
4. Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F; Murdaca G; Ghio M; Indiveri F
Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
[TBL] [Abstract][Full Text] [Related]
5. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
6. Strategies toward rheumatoid arthritis therapy; the old and the new.
Abbasi M; Mousavi MJ; Jamalzehi S; Alimohammadi R; Bezvan MH; Mohammadi H; Aslani S
J Cell Physiol; 2019 Jul; 234(7):10018-10031. PubMed ID: 30536757
[TBL] [Abstract][Full Text] [Related]
7. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
8. Treatment of rheumatoid arthritis.
Gaffo A; Saag KG; Curtis JR
Am J Health Syst Pharm; 2006 Dec; 63(24):2451-65. PubMed ID: 17158693
[TBL] [Abstract][Full Text] [Related]
9. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.
Capsoni F; Sarzi-Puttini P; Atzeni F; Minonzio F; Bonara P; Doria A; Carrabba M
Arthritis Res Ther; 2005; 7(2):R250-5. PubMed ID: 15743471
[TBL] [Abstract][Full Text] [Related]
10. New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval.
Bertele' V; Assisi A; Di Muzio V; Renzo D; Garattini S
Eur J Clin Pharmacol; 2007 Sep; 63(9):879-89. PubMed ID: 17646975
[TBL] [Abstract][Full Text] [Related]
11. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
12. Rheumatoid arthritis: new monoclonal antibodies.
Serio I; Tovoli F
Drugs Today (Barc); 2018 Mar; 54(3):219-230. PubMed ID: 29771256
[TBL] [Abstract][Full Text] [Related]
13. Biological response modifiers in the management of rheumatoid arthritis.
Louie SG; Park B; Yoon H
Am J Health Syst Pharm; 2003 Feb; 60(4):346-55. PubMed ID: 12625216
[TBL] [Abstract][Full Text] [Related]
14. Biologic agents for rheumatoid arthritis: 2008 and beyond.
Sweiss NJ; Hushaw LL
J Infus Nurs; 2009; 32(1 Suppl):S4-17; quiz S19-24. PubMed ID: 19142153
[TBL] [Abstract][Full Text] [Related]
15. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events.
Prado MS; Bendtzen K; Andrade LEC
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):985-995. PubMed ID: 28772079
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis.
Mok CC; Tsai WC; Chen DY; Wei JC
Expert Opin Biol Ther; 2016; 16(2):201-11. PubMed ID: 26560845
[TBL] [Abstract][Full Text] [Related]
17. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood lymphocytes from patients with rheumatoid arthritis are differentially sensitive to apoptosis induced by anti-tumour necrosis factor-alpha therapy.
Coury F; Ferraro-Peyret C; Le Cam S; Guerin S; Tebib J; Sibilia J; Bienvenu J; Fabien N
Clin Exp Rheumatol; 2008; 26(2):234-9. PubMed ID: 18565243
[TBL] [Abstract][Full Text] [Related]
19. Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents.
Atzeni F; Talotta R; Masala IF; Gerardi MC; Casale R; Sarzi-Puttini P
Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):500-510. PubMed ID: 31174819
[TBL] [Abstract][Full Text] [Related]
20. Modern treatment strategies in rheumatoid arthritis.
Hetland ML
Dan Med Bull; 2011 Nov; 58(11):B4320. PubMed ID: 22047935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
